2021
DOI: 10.1007/s12028-021-01221-4
|View full text |Cite
|
Sign up to set email alerts
|

Association of Dose of Intracranial Hypertension with Outcome in Subarachnoid Hemorrhage

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
20
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 24 publications
(21 citation statements)
references
References 19 publications
1
20
0
Order By: Relevance
“…Furthermore, other approaches have been made to quantify the effects of intracranial hypertension. For example, the ICP dose, i.e., the combination of ICP intensity and the duration of that episode, has in one recent study been more strongly associated with unfavorable outcome than ICP above certain fixed thresholds [ 4 ]. On balance, despite the negative results in this paper, higher ICP for longer periods of time does seem to exert a negative effect on the brain and worsen outcome.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, other approaches have been made to quantify the effects of intracranial hypertension. For example, the ICP dose, i.e., the combination of ICP intensity and the duration of that episode, has in one recent study been more strongly associated with unfavorable outcome than ICP above certain fixed thresholds [ 4 ]. On balance, despite the negative results in this paper, higher ICP for longer periods of time does seem to exert a negative effect on the brain and worsen outcome.…”
Section: Discussionmentioning
confidence: 99%
“…Intracranial hypertension after SAH is associated with poor outcomes [30][31][32]. Existing SAH international guidelines [5,16,18] do not provide specific recommendations regarding ICP/CPP monitoring and treatment despite there being several reasons for doing so [33].…”
Section: Icp Monitoring and Intracranial Hypertension Managementmentioning
confidence: 99%
“…These results should be interpreted with caution as all patients in the ICP-guided therapy subgroup experienced intracranial hypertension, which is a well-known determinant of poor outcome in SAH patients, while only 61% had this complication in the ICP/ PbtO 2 group. Unfortunately, we could not assess the "intensity" (the highest ICP value) and "duration" of intracranial hypertension, which have both been shown to predict neurological outcome in this setting 48 . However, brain hypoxia is also a determinant of UO after SAH and deserves further attention in the management of these patients, as for intracranial hypertension.…”
Section: Discussionmentioning
confidence: 99%